Middle East & Africa Molecular Diagnostics for Infectious Disease Market

The Middle East & Africa molecular diagnostics for infectious disease market was valued at US$ 134.22 million in 2022 and is expected to reach US$ 301.21 million by 2030; it is estimated to grow at a CAGR of 10.6% from 2022 to 2030.

Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the Middle East & Africa Molecular Diagnostics for Infectious Disease Market

Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.

Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Overview

The UAE, Saudi Arabia, and South Africa are major countries in the Middle East & Africa. The market in the Middle East & Africa is anticipated to grow during 2022–2030 due to the rising prevalence of various infectious diseases, and conducive environment created by government initiatives in terms of funding and healthcare-related policies. In March 2023, Mylab Discovery Solutions, one of the leading biotech companies in India, announced an exclusive strategic partnership with AstraGene LLC, the first molecular manufacturing company in the UAE, to develop automated molecular diagnostics solutions for markets in the UAE and Kuwait. Under the agreement, Mylab and AstraGene would codevelop molecular diagnostic solutions such as reagents, kits, and fully automated devices. This partnership marks Mylab’s latest international market expansion and supports the company's long-term growth strategy to make high-quality diagnostics accessible to customers across the world. Such strategic initiatives taken by market players for the introduction of novel solutions in the Middle East & Africa are fueling the growth of the molecular diagnostic for infectious disease market.

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Segmentation

The Middle East & Africa molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022.

The Middle East & Africa molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022.

Based on application, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.

Based on country, the Middle East & Africa molecular diagnostics for infectious disease market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa molecular diagnostics for infectious disease market in 2022.

F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA are some of the leading companies operating in the Middle East & Africa molecular diagnostics for infectious disease market.    

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Strategic Insights

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Segmentation Analysis

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Report Highlights

Middle East & Africa Molecular Diagnostics for Infectious Disease Report Scope

Middle East & Africa Molecular Diagnostics for Infectious Disease Market Country and Regional Insights